These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 28703313)

  • 41. Mesenchymal stem cells as carrier of the therapeutic agent in the gene therapy of blood disorders.
    Shomali N; Gharibi T; Vahedi G; Mohammed RN; Mohammadi H; Salimifard S; Marofi F
    J Cell Physiol; 2020 May; 235(5):4120-4134. PubMed ID: 31691976
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Update on Mesenchymal Stem Cells: A Crucial Player in Cancer Immunotherapy.
    Taeb S; Rostamzadeh D; Mafi S; Mofatteh M; Zarrabi A; Hushmandi K; Safari A; Khodamoradi E; Najafi M
    Curr Mol Med; 2024; 24(1):98-113. PubMed ID: 36573062
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Suicide-gene transfection of tumor-tropic placental stem cells employing ultrasound-responsive nanoparticles.
    Paris JL; de la Torre P; Cabañas MV; Manzano M; Flores AI; Vallet-Regí M
    Acta Biomater; 2019 Jan; 83():372-378. PubMed ID: 30414488
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Progress on utilizing mesenchymal stem cells as cellular delivery system for targeting delivery of as drug/gene for anti-tumor therapy].
    Li A; Zhang T; Gao J
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2020 May; 49(1):20-34. PubMed ID: 32621413
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma.
    Kim SM; Lim JY; Park SI; Jeong CH; Oh JH; Jeong M; Oh W; Park SH; Sung YC; Jeun SS
    Cancer Res; 2008 Dec; 68(23):9614-23. PubMed ID: 19047138
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vector-producing tumor-tracking multipotent mesenchymal stromal cells for suicide cancer gene therapy.
    Okada T; Ozawa K
    Front Biosci; 2008 Jan; 13():1887-91. PubMed ID: 17981676
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mesenchymal stem cells as a novel carrier for targeted delivery of gene in cancer therapy based on nonviral transfection.
    Hu YL; Huang B; Zhang TY; Miao PH; Tang GP; Tabata Y; Gao JQ
    Mol Pharm; 2012 Sep; 9(9):2698-709. PubMed ID: 22862421
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mesenchymal stem cells as therapeutics and vehicles for gene and drug delivery.
    Porada CD; Almeida-Porada G
    Adv Drug Deliv Rev; 2010 Sep; 62(12):1156-66. PubMed ID: 20828588
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genetically engineered mesenchymal stem cells as a nitric oxide reservoir for acute kidney injury therapy.
    Huang H; Qian M; Liu Y; Chen S; Li H; Han Z; Han ZC; Chen XM; Zhao Q; Li Z
    Elife; 2023 Sep; 12():. PubMed ID: 37695201
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Baculovirus-transduced bone marrow mesenchymal stem cells for systemic cancer therapy.
    Bak XY; Yang J; Wang S
    Cancer Gene Ther; 2010 Oct; 17(10):721-9. PubMed ID: 20539321
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Progress and problems with the use of suicide genes for targeted cancer therapy.
    Karjoo Z; Chen X; Hatefi A
    Adv Drug Deliv Rev; 2016 Apr; 99(Pt A):113-128. PubMed ID: 26004498
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Engineering mesenchymal stem cells: a novel therapeutic approach in breast cancer.
    Heidari R; Gholamian Dehkordi N; Mohseni R; Safaei M
    J Drug Target; 2020; 28(7-8):732-741. PubMed ID: 32463709
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nanotechnology and bioengineering approaches to improve the potency of mesenchymal stem cell as an off-the-shelf versatile tumor delivery vehicle.
    Taheri M; Tehrani HA; Dehghani S; Alibolandi M; Arefian E; Ramezani M
    Med Res Rev; 2024 Jul; 44(4):1596-1661. PubMed ID: 38299924
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic effect of suicide gene-transferred mesenchymal stem cells in a rat model of glioma.
    Kosaka H; Ichikawa T; Kurozumi K; Kambara H; Inoue S; Maruo T; Nakamura K; Hamada H; Date I
    Cancer Gene Ther; 2012 Aug; 19(8):572-8. PubMed ID: 22744211
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeted antitumor therapy mediated by prodrug-activating mesenchymal stromal cells.
    Kucerova L; Durinikova E; Toro L; Cihova M; Miklikova S; Poturnajova M; Kozovska Z; Matuskova M
    Cancer Lett; 2017 Nov; 408():1-9. PubMed ID: 28838843
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The future of mesenchymal stem cell-based therapeutic approaches for cancer - From cells to ghosts.
    Mohr A; Zwacka R
    Cancer Lett; 2018 Feb; 414():239-249. PubMed ID: 29175461
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gene Delivery Approaches for Mesenchymal Stem Cell Therapy: Strategies to Increase Efficiency and Specificity.
    Oggu GS; Sasikumar S; Reddy N; Ella KKR; Rao CM; Bokara KK
    Stem Cell Rev Rep; 2017 Dec; 13(6):725-740. PubMed ID: 28815481
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Regulated Mesenchymal Stem Cells Mediated Colon Cancer Therapy Assessed by Reporter Gene Based Optical Imaging.
    Kalimuthu S; Zhu L; Oh JM; Lee HW; Gangadaran P; Rajendran RL; Baek SH; Jeon YH; Jeong SY; Lee SW; Lee J; Ahn BC
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29584688
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mesenchymal stem cells: isolation, in vitro expansion and characterization.
    Beyer Nardi N; da Silva Meirelles L
    Handb Exp Pharmacol; 2006; (174):249-82. PubMed ID: 16370331
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synergistic effects of genetically engineered stem cells expressing cytosine deaminase and interferon-β via their tumor tropism to selectively target human hepatocarcinoma cells.
    Yi BR; Hwang KA; Kang NH; Kim SU; Jeung EB; Kim HC; Choi KC
    Cancer Gene Ther; 2012 Sep; 19(9):644-51. PubMed ID: 22790964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.